Tenderwize
Retour à la recherche

Open-House-Biologika-Rabattverträge 2025-26 - Insulin lispro

Techniker Krankenkasse·Hamburg, Germany·Deadline Oct 30, 2027 · 430 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-26 - Insulin lispro (ATC: A10AB04, Wirkstärke: 100 U/ml)

50/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

40 / 100

Facteurs de risque

No estimated contract value or volume is provided, making it difficult to assess potential revenue.

The procedure is not a standard public procurement; it relies on specific SGB V and AMG provisions. The dispute resolut...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Pharmaceutical discount agreements for Insulin lispro (ATC: A10AB04, 100 U/ml)
  • Open House procedure with uniform conditions, no negotiations
Afficher le résumé complet

Open House procedure by Techniker Krankenkasse and other German health insurance companies to conclude discount agreements (Rabattverträge) for Insulin lispro (ATC: A10AB04, 100 U/ml) under § 130a Abs. 8 SGB V. The procedure is open to all qualified pharmaceutical entrepreneurs, with no exclusivity, and contracts can be concluded continuously until the end date. The contract term is 24 months from November 1, 2025, to October 31, 2027. No estimated value is provided.

Risques

No estimated contract value or volume is provided, making it difficult to assess potential revenue.

The procedure is not a standard public procurement; it relies on specific SGB V and AMG provisions. The dispute resolut...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG
  • Registered office in Germany, EU, or EEA (§ 9 Abs. 2 AMG)
  • Valid marketing authorization for the product (§ 21 AMG) or equivalent right

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified; all qualifying participants are accepted.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-26 - Insulin lispro

Conclusion of discount agreements for the active substance Insulin lispro (ATC: A10AB04, 100 U/ml) under an Open House procedure. No negotiations, uniform conditions, non-exclusive.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Oct 2025 - Oct 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; all qualifying participants are accepted.

Date limite

Deadline Oct 30, 2027

Détails de la procédure

Date de publication
09 Sep 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
589353-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3